Drug Trial Radar · NCT07565441
Drug-Drug Interactions of JMKX003142 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Nov 15, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hangyu Pharmaceutical Co., Ltd.
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants. The study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.
Conditions
- ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
JMKX003142 tabletsDrug
3mg once daily (QD) on Day 1 and Day 7
Fluconazole CapsulesDrug
400mg QD on Day 4, 200mg QD from Day 5 to Day 9
Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)Drug
Midazolam Oral Solution 2mg, Rosuvastatin Calcium Tablets 5mg and Digoxin Tablets 0.25mg QD on Day 1, Day 8 and Day 21
Cyclosporine Soft CapsulesDrug
100 mg twice daily (BID) from Day 4 to Day 9
Omeprazole Enteric-coated TabletsDrug
40mg QD from Day 4 to Day 8
Efavirenz TabletsDrug
600mg QD from Day 4 to Day 12
JMKX003142 tabletsDrug
6mg QD from Day 8 to Day 25
JMKX003142 tabletsDrug
6mg QD on Day 1 and Day 8
JMKX003142 tabletsDrug
6mg QD on Day 1 and Day 10
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of JMKX003142 and its metabolitesTime frame: for 120 hours
- Area Under Curve (AUC) of JMKX003142 and its metabolitesTime frame: for 120 hours
- Maximum Plasma Concentration (Cmax) of Midazolam and its metabolitesTime frame: for 144 hours
- Area Under Curve (AUC) of of Midazolam and its metabolitesTime frame: for 144 hours
- Maximum Plasma Concentration (Cmax) of RosuvastatinTime frame: 144 hours
- Area Under Curve (AUC) of of RosuvastatinTime frame: for 144 hours
- Maximum Plasma Concentration (Cmax) of DigoxinTime frame: for 144 hours
- Area Under Curve (AUC) of DigoxinTime frame: for 144 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.